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Abstract
Hepatocellular carcinoma is a highly deadly malignancy, accounting for approximately
800,000 deaths worldwide every year. Mutation of the p53 tumor suppressor gene is a com-
mon genetic change in HCC, present in 30% of cases. p53R175H (corresponding to
p53R172H in mice) is a hotspot for mutation that demonstrates “prometastatic” gain-of-func-
tion in other cancer models. Since the frequency of p53 mutation increases with tumor
grade in HCC, we hypothesized that p53R172H is a gain-of-function mutation in HCC that
contributes to a decrease in tumor-free survival and an increase in metastasis. In an HCC
mouse model, we found that p53R172H/flox mice do not have decreased survival, increased
tumor incidence, or increased metastasis, relative to p53flox/flox littermates. Analysis of cell
lines derived from both genotypes indicated that there are no differences in anchorage-inde-
pendent growth and cell migration. However, shRNA-mediated knockdown of mutant p53 in
p53R172H-expressing HCC cell lines resulted in decreased cell migration and anchorage-in-
dependent growth. Thus, although p53 mutant-expressing cells and tumors do not have en-
hanced properties relative to their p53 null counterparts, p53R172H-expressing HCC cells
depend on this mutant for their transformation. p53 mutants have been previously shown to
bind and inhibit the p53 family proteins p63 and p73. Interestingly, we find that the levels of
p63 and p73 target genes are similar in p53 mutant and p53 null HCC cells. These data sug-
gest that pathways regulated by these p53 family members are similarly impacted by
p53R172H in mutant expressing cells, and by alternate mechanisms in p53 null cells, result-
ing in equivalent phenotypes. Consistent with this, we find that p53 null HCC cell lines dis-
play lower levels of the TA isoforms of p63 and p73 and higher levels of ΔNp63. Taken
together these data point to the importance of p63 and p73 in constraining HCC
progression.
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Introduction
Liver cancer accounts for approximately 800,000 deaths annually and up to 85% of these can-
cers are hepatocellular carcinoma (HCC) [1]. Curative treatments for HCC are restricted to
surgical resection of the tumor, or liver transplantation. Unfortunately, as few as 30% of pa-
tients are eligible for resection or transplant due to the presence of extensive liver disease, inva-
sive HCC, or metastasis [2,3]. Moreover, relapse rates post-resection are over 60%, suggesting
the presence of undetected disease dissemination at the time of surgery [4]. At present, there
are no curative options for patients with unresectable disease. These patients are commonly
treated with Sorafenib, which extends survival by 2.8 months [5]. Therefore, understanding the
molecular mechanisms underlying HCC dissemination is of great importance for improving
the prognosis for HCC patients.
Point mutations in the TP53 tumor suppressor gene occur at a high frequency in many
tumor types [6]. In HCC, TP53 gene mutation is observed in over 30% of cases [7]. Interesting-
ly, TP53mutations are absent in hepatic adenomas, while their frequency increases with tumor
grade and differentiation status, occurring in 54% of poorly differentiated HCCs [8,9]. Indeed,
TP53mutations are associated with a higher rate of relapse and decreased overall survival in
HCC [7,10]. Furthermore, in a non-metastatic HCC mouse model, deletion of Trp53 resulted
in tumors with more aggressive histology and increased metastasis to the lungs [11]. Together,
these findings suggest a specific role for p53 inactivation in promoting HCC progression.
Some p53 missense mutations have been found to exert both dominant negative and gain-
of-function effects [12]. One particular mutation, p53R172H, which corresponds to human p53
hotspot R175H, has been shown to inhibit wild-type p53 function [13–15]. Aside from inacti-
vating the wild-type protein, p53R172H also displays gain-of-function properties in breast and
pancreatic cancer, with phenotypes including increased tumor initiation, invasion, and metas-
tasis relative to p53 null controls [16–19]. Moreover, mice bearing a single knock-in LSL-
p53R172H allele developed more carcinomas than p53 null counterparts, consistent with gain-
of-function properties of the mutant protein [20]. Finally, tumors expressing p53R172H were
more metastatic than tumors deleted for p53 [20,21].
Whether p53 mutants display gain-of-function activity in liver cancer is unclear. A prior
study found that overexpression of several p53 mutants in HCC cell lines decreased apoptosis
in response to stress [22]. In another study, ectopic expression of an aflatoxin-induced
p53R249S mutant did not confer any growth benefit to an HCC cell line. However, in an HCC
cell line with endogenous expression of p53R249S, p53 knockdown decreased proliferation and
increased cell death [23]. These data demonstrate that the response of HCC cell lines to mutant
p53 may vary depending on endogenous or exogenous expression of these mutants. Addition-
ally, cell context and the type of p53 mutant may also be important factors dictating p53 gain-
of-function activity in HCC.
Yet, p53 mutants do not display gain-of-function properties in every context. In a UV-in-
duced skin carcinogenesis model, the p53R270H mutant exerted dominant-negative effects on
the wild-type p53 protein and enhanced tumor formation and decreased survival [24]. Howev-
er, mice expressing only the p53R270H mutant in the skin did not have enhanced tumor forma-
tion or decreased survival relative to animals null for p53, suggesting the absence of gain-of-
function properties in this tissue [24].
The R172H mutation alters the tertiary structure of the p53 protein and is therefore classi-
fied as a structural mutant [25]. This mutant is thought to bind and inhibit the p53-related
transcription factors p63 and p73, resulting in gain-of-function effects [21,26]. Expression of
TP63 and TP73 genes can be directed from two distinct promoters, resulting in TA or ΔN iso-
forms [27]. In general, TA isoforms are believed to act as tumor suppressors, while the ΔN
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isoforms are thought to be oncogenic. Mice with heterozygous deletion of Trp63 or Trp73 de-
velop spontaneous tumors with accompanying loss of heterozygosity, indicating that these
transcription factors act as tumor suppressors [28]. In addition, inhibition of these other p53
family members exacerbates tumor development and progression in p53-deficient animals,
suggesting that they have non-overlapping tumor suppressor functions with p53 [28,29].
Moreover, recent work demonstrated that specific deletion of the ΔN isoforms of inhibited
growth of p53-deficient tumors [30].
However, unlike the pattern of TP53 inactivation seen in HCC patient specimens, mutations
or allelic losses have not been detected in the TP63 and TP73 genes [31,32]. Interestingly,
TAp73 and TAp63 levels are increased in HCCs as compared to normal liver [31,33]. In the
case of p73, higher expression levels are correlated with p53 inactivation [34,35] and poorer
prognosis [36]. Yet in the mouse, concomitant deletion of Trp53 and Trp73 promotes HCC de-
velopment [28].
Given the absence of homozygous TP53 deletion, and because p53R172H has been shown to
contribute to metastasis in other mouse models, we investigated whether p53R172H enhances
HCC progression relative to p53 nullizygosity. Interestingly, we find that the p53R172H mutant
does not enhance tumor development or metastasis in vivo, relative to p53 deficiency. Further,
cell lines derived from p53 null and p53R172H-expressing tumors display similar phenotypes in
vitro. Intriguingly, we find that p53R172H-expressing HCC cells are dependent on the sustained
expression of this mutant for their transformed phenotype. Finally, our data suggest that im-
pairment of p63 and p73 function occurs in all of the HCC cell lines evaluated, suggesting that
inhibition of these transcription factors may be a critical step in HCC pathogenesis.
Materials and Methods
Ethics Statement
All animal experiments were reviewed and approved by the University of Massachusetts Medi-
cal School Institutional Animal Care and Use Committee. Animals were housed in specific
pathogen free facilities with abundant food and water.
Animal Studies
LSL-Trp53R172H mice [20] were obtained and crossed with Albumin-tva, p53flox/flox, Albumin-
cremice [37]. Albumin-tva, LSL-Trp53R172H/flox, Albumin-cremice were crossed to Albumin-
tva, Trp53flox/flox, Albumin-cremice in order to obtain littermates for direct comparison. Three
day-old pups were injected in the liver with 2x106 DF1 cells producing RCAS-PyMT in 5μL of
serum free DMEM [37]. Mice in the tumor study were divided into either survival or time
point cohorts. In the survival study, a cohort of 30 injected mice were sacrificed when distress
was apparent as defined by our University of Massachusetts Medical School Institutional Ani-
mal Care and Use Committee approved animal protocol (hunched posture, poor grooming, re-
duced activity, and altered respiratory pattern), or at the age of 9 months, whichever came first.
Euthanasia was performed by lethal CO2 administration followed by bilateral pneumothorax, a
method consistent with the recommendations of the Panel on Euthanasia of the American Vet-
erinary Medical Association. Mice whose cause of death was likely due to tumor burden or
metastatic disease were counted in the Kaplan-Meier curve, while mice that died without pri-
mary HCC were censored. Kaplan-Meier statistics were calculated using the Log-rank test. An
additional cohort of mice was assigned to time point groups of 3, 6, or 8 months as they were
enrolled in the study. Mice were sacrificed at these time points, or when distress was apparent.
Individual tumors were counted and measured in three dimensions. Tumor volume was calcu-
lated using the formula for an ellipsoid (V = (4/3)πL/2W/2H/2, where L, W and H are the
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length, width and height of the tumor, respectively), and tumor burden/mouse was the sum of
each tumor volume per animal. For both the time point and survival studies, liver and lung tis-
sues from each mouse were harvested. Portions of fresh HCC were excised from harvested tis-
sue in order to establish cell lines. Additionally, portions of tumor were flash frozen in liquid
nitrogen for later isolation of nucleic acids and protein. Remaining liver and lung tissue from
each animal were formalin-fixed and paraffin-embedded for further analysis.
Cell culture
Tumor-derived cell lines were isolated de novo by mincing mouse tumor tissue and culturing
in high-glucose DMEM with 10% fetal bovine serum (FBS) and 1% Penicillin/Streptomycin
(Pen/Strep). Appropriate p53 expression was confirmed by immunoblot.
Stable p53 knockdown was performed using a pGIPZ library shRNA directed to mouse p53
(Thermo Scientific, V3LHS_646511). An empty pGIPZ plasmid was used as a control. Lentivi-
ruses were produced in 293T cells that were transfected with plasmids containing envelope gly-
coprotein, required packaging sequences, and pGIPZ plasmid. Transfections were performed
using Effectene Transfection Reagent (QIAGEN, 301425). HCC target cells were infected with
1 mL of lentiviral supernatant in a well of a 6-well plate in the presence of 1μg polybrene. Fol-
lowing infection, cells were selected in 6μg/mL puromycin before experimental analysis. To in-
duce cell stress and p53 expression, 50nM Gemcitabine was added to growth media for 24
hours before generating protein lysates.
Transwell migration assay
Migration of cell lines was assessed by plating 2.5x104 cells on a migration insert (BD Biosci-
ences, 354578) in serum-free DMEM. DMEM containing 10% FBS was placed in the lower
chamber as a chemoattractant. After 20 hours, non-migrating cells were removed from the
upper side of the membrane, and migrating cells on the lower side of the membrane were
stained with Giemsa. The migrating cells per well were determined by averaging the cell num-
bers across 5 fields at 100X magnification. Error bars on migration assay graphs are representa-
tive of standard deviation. p-values were calculated by Student’s t-test.
Soft agar colony assay
For soft agar colony formation experiments, a 1.4% hard agar solution was combined with 2X
DMEM with 20% FBS and 2% Pen/Strep and plated onto 100mm tissue culture plates. After
hardening, 1x105 cells were mixed with equal parts of a 0.8% soft agar solution and 2X growth
media. After the soft agar solution hardened, 8ml of 1X growth media was added to the dishes,
which were incubated for 2 weeks at 37°C. Colonies were counted in 20 fields per plate at 100X
magnification. Size exclusion was used to ensure that colonies had grown in the dish, and were
not just cell clumps. Error bars on soft agar colony experiments are representative of standard
deviation. p-values were calculated by Student’s T-test.
Immunoblotting
Protein lysates from cell lines were generated in RIPA buffer, and concentrations were normal-
ized by Bradford Assay. 20μg of lysate were used for each Western blot sample. 10% acrylamide
gels were used for SDS-PAGE, and subsequently blotted onto PVDF. Western blots were
blocked for one hour at room temperature in 7.5% nonfat dry milk in TBS. Antibodies for
Western blotting were diluted in either 5% nonfat dry milk or 5% BSA. Antibodies used were:
p53 antibody (1:2000, Cell Signaling 1C12), p21 antibody (1:1000, Santa Cruz sc-6246), TAp63
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antibody (1:500, Biolegend 618901), ΔNp63 antibody (1:500, Biolegend 619001), Total p63 an-
tibody (1:500 Santa Cruz, ac-8431), TAp73 antibody (1:500 Novus 24737), Total p73 antibody
(1:500 Imgenex). GAPDH antibody (1:1000, Millipore, MAB374) and rabbit polyclonal β-actin
antibody (1:2000, sc-1615-R).
Immunohistochemistry
Portions of each tumor were fixed in formalin and embedded in paraffin. Tissue sections were
deparaffinized with heat and rehydrated in decreasing alcohol concentrations. After rehydra-
tion, antigen retrieval was performed by microwaving slides in Antigen Unmasking Solution
(Vector, H-3300). After cooling, endogenous peroxides were inactivated by adding 3% hydro-
gen peroxide for 10 minutes. Slides were blocked in goat serum in PBS for one hour at room
temperature. Ki67 primary antibody (1:500, Abcam, ab66155) and p53 antibody (1:500, Leica
Biosystems, CM5) were diluted in goat serum in PBS and incubated on slides overnight at 4°C.
Biotinylated Rabbit secondary antibody was diluted in goat serum in PBS and added to the
slides for one hour at room temperature. Goat serum, secondary antibody, and developing re-
agents were from Vector ABC kits (PK-4001). Pigment was developed in the tissues using a
NovaRed Peroxidase Substrate (Vector, SK-4800). After development, slides were co-stained in
hematoxylin, dehydrated, and mounted.
p53 family target gene analysis
RNA from cell lines was isolated using Trizol, and converted to cDNA using First-Strand
cDNA synthesis kit (Invitrogen, 18080–051). qRT-PCR was performed using Quanta Perfecta
SYBR Green (VWR, 95072) in an ABI 7300 machine using 50ng cDNA. p63 and p73 targets
were amplified using the primers listed in S1 Table.
For qPCR studies on the tumor-derived cell line panel, average Ct values for each cell line
were determined for both the target gene and β-actin endogenous control. Ct values for each
individual cell line were normalized to the average Ct value for the p53-null cell lines, so that
each cell line fold change is calculated in relationship to the average of four p53fl/fl cell lines. All
individual lines were normalized to β-actin as an endogenous reference.
For assaying p53 knockdown cell lines, each shRNA-infected line was normalized to its re-
spective pGIPZ-infected control, after normalizing to an endogenous reference. In each case
the Comparative Ct Method was used to calculate fold change, where fold change = 2
-ΔΔCT.
Results
p53R172H does not promote HCC development, progression, and
metastasis in vivo
To determine if p53R172H exhibits gain-of-function properties in HCC, we generated Albumin-
tva, LSL-Trp53R172H/flox, Albumin-cremice (hereafter referred to as p53R172H mice) and Albu-
min-tva, Trp53flox/flox, Albumin-cre (p53fl/fl) littermates. These mice were injected with DF1
cells producing RCAS-PyMT to induce HCC, as done previously [11,37]. In this model, loss of
p53 function promotes metastasis, which can be enhanced through concomitant deletion of
Ink4a/Arf [11,37]. Therefore, if the p53R172H mutant has gain-of-function properties, these
should be observed in this model as enhanced tumor progression. We found that the presence
of the mutated p53 allele did not impact tumor-free survival (Fig 1A). Immunohistochemical
staining of tumor specimens detected nuclear p53 in p53R172H tumors but not p53fl/fl tumors,
demonstrating specific expression within the p53 mutant tumors (S1 Fig). Analysis of genomic
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Fig 1. p53R172H does not result in gain-of-function properties in an HCCmousemodel. A) Kaplan-Meier
curve displaying tumor free survival of p53fl/fl and p53R172H littermates. Mice were assessed over a period of 9
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DNA isolated from a subset of liver tumors also confirmed recombination of the LSL cassette
in the p53R172H tumors confirming activation of the mutant p53 allele (S1 Fig).
To ascertain if p53R172H accelerated tumor onset in this model, a separate cohort of animals
was euthanized at 3, 6, or 8 months of age, unless the mouse displayed signs of high tumor bur-
den and had to be euthanized in accordance with our approved animal protocol. This cohort
also did not display different rates of tumor formation or metastasis at any time point evaluated
(S2 Table).
In addition to these characteristics, we assessed whether tumor burden or tumor histology
differed between tumors induced in p53R172H and p53fl/fl mice. We found that the total tumor
burden for each mouse in the survival study was not statistically different between the two
groups (Fig 1B). Moreover, the tumors induced in the two groups appeared to be histologically
similar. Evaluation of hematoxylin and eosin (H&E) stained tissue sections demonstrated that
regions of unique HCC histology appear at similar frequencies in both groups (Fig 1C). Ki67
staining of tumor tissues also revealed that the proliferation rates are similar between tumors
with or without the p53 mutant (S2 Fig). Indeed, variation between tumors within the same
group was greater than variation between the two groups. In addition, p53R172H and p53fl/fl
mice did not have significantly different rates of metastasis (Chi-Square, p = 0.2918; Fisher’s
Exact Test, p = 0.3473), with 2/12 p53fl/fl mice, and 3/8 p53R172H mice displaying metastasis to
the lungs or within the peritoneal cavity (Fig 1D and S3 Fig). Collectively, these data demon-
strate that the presence of the p53R172H mutant does not enhance HCC development and pro-
gression in vivo.
Tumor-derived cell lines from p53R172H HCCs do not display enhanced
properties relative to p53fl/fl-derived cell lines
We generated a collection of HCC cell lines isolated from tumors induced in p53 null and p53
mutant livers. Eight (8) tumor cell lines, 4 from each group, were compared to determine
whether the presence of p53R172H enhanced transformation-associated phenotypes in vitro.
p53R172H tumor-derived cell lines expressed p53 as expected, while p53fl/fl cell lines had no de-
tectable p53 (Fig 2A). Importantly, expression of the p53 target gene p21 was not induced in
p53R172H cell lines relative to p53fl/fl lines following gemcitabine treatment, consistent with the
absence of functional p53 protein (Fig 2A).
To ascertain whether p53R172H enhances HCC cell migration, we performed transwell mi-
gration assays, and found that p53 null cell lines migrated as well as p53 mutant lines (Fig 2B).
Thus, the presence of mutant p53 does not enhance this property, an outcome consistent with
the similar rates of metastasis observed in vivo in our HCC mouse model. Similarly, we found
that p53R172H does not enhance anchorage-independent growth, relative to p53 nullizygosity,
as measured by a soft agar colony formation assay (Fig 2C). These data are consistent with our
finding of similar survival rates and tumor burden in the HCC mouse model. Thus, in combi-
nation with our in vivo data, our in vitro results suggest that the p53R172H mutant does not pro-
mote an enhanced tumor phenotype in HCC.
months and sacrificed when illness was apparent. Only mice whose death was perceived to be due to HCC
were included, otherwise the mouse was censored. Censored animals are represented in the figure as tick
marks on the day of death. B) Total tumor burden in the survival cohort. Individual tumor volume was
calculated using the formula for an ellipsoid. All of the tumor volumes for a given mouse were summed to
arrive at the tumor burden per animal. C) H&E staining demonstrating commonly seen architecture in HCC
mouse model. D) Number of p53R172H and p53fl/fl mice with (grey) or without (black) grossly visible
metastatic lesions.
doi:10.1371/journal.pone.0123816.g001
Mutant p53 and Hepatocellular Carcinoma Progression
PLOS ONE | DOI:10.1371/journal.pone.0123816 April 17, 2015 7 / 16
p53R172H is required for HCC cell transformation
In previous studies analyzing the gain-of-function properties of mutant p53 proteins, a hall-
mark experiment was the demonstration that knockdown of mutant p53 abrogated the trans-
formed phenotype [20,22]. We therefore determined whether depletion of mutant p53
similarly impacted our HCC cell lines. We knocked down p53 in 2 cell lines derived from
p53R172H tumors and knockdown confirmed by immunoblotting (Fig 3A). As a control for po-
tential off-target effects, we introduced the p53-targeting shRNA into a p53 null cell line. We
observed that p53 knockdown impaired cell migration (Fig 3B) and soft agar colony formation
(Fig 3C) relative to controls in cells expressing the R172H mutant, suggesting that mutant p53
is required for these phenotypes in p53R172H-expressing HCC cell lines. Importantly, expres-
sion of the p53-targeting shRNA in a p53 null cell line did not impact cell migration or soft
agar colony formation, confirming that these effects result from suppression of mutant p53
and not off-target effects.
p53 family transcriptional activity is similar in p53 null and p53R172H-
expressing HCC lines
The above data suggest that while p53R172H is required for transformation-associated pheno-
types in HCC cells expressing the mutant, the presence of mutant p53 does not enhance these
properties beyond what is observed in p53 null cell lines. This suggests, potentially, that similar
pathways are impacted in both contexts. Since p53R172H is known to bind to, and inhibit, other
p53 family transcription factors as a mechanism of its gain-of-function properties in other can-
cer types, we examined the mRNA levels of a collection of genes known to be regulated by the
related p63 and p73 proteins. Previously published studies have described several genes regu-
lated by p63 and p73. We curated a collection of published target genes from such studies
[38–40], and selected a subset of these genes that are involved in a range of cellular processes
for characterization in our HCC cell lines. We found that the mRNA levels of p53 family target
Fig 2. Cell lines derived from p53R172H-expressing HCCs do not display enhanced properties when
compared to p53-null HCCs. A) Immunoblots demonstrating expression of p53 and p21 in selected mouse
tumor-derived cell lines. B) Transwell migration assay of HCC cell lines derived from p53fl/fl and p53R172H
tumors. C) Soft agar colony formation assay of HCC cell lines derived from p53fl/fl and p53R172H tumors.
doi:10.1371/journal.pone.0123816.g002
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genes involved in cell signaling (Fig 4A), DNA damage (Fig 4B), and cellular processes
(Fig 4C), are unchanged between p53R172H and p53fl/fl cell lines.
p53 family target gene expression is increased upon knockdown of
mutant p53
Tumor-derived cell lines from our mouse model containing p53R172H do not have enhanced
tumor properties as compared to cell lines null for p53. This could in part be attributed to simi-
lar levels of p53 family transcriptional activity as shown in Fig 4. However, upon knockdown
of p53R172H, cell transformation properties decrease, indicating that mutant p53 is required for
the phenotypes displayed in these cells (Fig 3).
We therefore evaluated a subset of the target genes analyzed in Fig 4, covering multiple cel-
lular processes, to determine whether their mRNA levels increased upon knockdown of
p53R172H. p53 knockdown was performed in two additional p53R172H-derived cell lines and
Fig 3. p53R172H is required for transformation-related phenotypes in HCC cell lines. A) Immunoblot of
p53 depicting 3 HCC cell lines infected with shRNA as compared to an empty vector control labeled pGIPZ.
B) Transwell migration assay of p53 shRNA-infected HCC cell lines. A p53-null cell line was used as an
experimental control. p-values, calculated by Student’s t-test, are 0.020 and 0.022 for R172H lines 1 and 2,
respectively. The number of migrating cells in each pGIPZ control infection was set to 100%. C) Soft agar
colony formation assay of p53 shRNA-infected HCC cell lines. A p53-null cell line was used as an
experimental control. p-values, calculated by Student’s t-test are 0.044 and 0.004 for R172H lines 1 and 2,
respectively. The number of colonies for each pGIPZ control infection was set to 100%.
doi:10.1371/journal.pone.0123816.g003
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knockdown confirmed by immunoblot (Fig 5A). When added to the 2 knockdown lines previ-
ously characterized (Fig 3), this generated a panel of 4 knockdown cell lines, and paired con-
trols, for analysis. We found that the levels of p21, Cldn1, and Rad51 were commonly
increased in knockdown cells relative to paired control cells (Fig 5B). This suggests that mutant
p53 suppressed their expression, potentially by functionally interfering with p63 and p73.
The results above suggest that p63 and p73 are inhibited by mutant p53. They additionally
suggest that p63 and p73 are inhibited by an alternate mechanism in p53 null HCC cells. We
Fig 4. p53R172H and p53fl/fl HCC cell lines do not display differential expression of p53 family
transcriptional targets. A) qRT-PCR of DNA damage-related targets of p53 family transcription factors. B)
qRT-PCR analysis of p53 family targets related to cell signaling. C) qRT-PCR analysis of p53 family targets
related to other cell processes. Dark circles indicate p53fl/fl cell lines, while open circles are p53R172H
cell lines.
doi:10.1371/journal.pone.0123816.g004
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Fig 5. Knockdown of p53 in p53R172H HCC cell lines results in increased expression of several p53
family transcriptional targets. A) Immunoblot demonstrating knockdown of p53 in cell lines derived from
p53R172H HCCs as compared to pGIPZ empty vector control infections. B) Quantitative RT-PCR analysis of
p53 family transcriptional targets in four mouse HCC cell lines with knockdown of p53R172H. Ct values in each
sample were normalized to β-Actin as an endogenous reference. Fold changes were calculated by
normalizing all samples to the average Ct value of the cell line’s pGIPZ control. The Comparative Ct method
was used for fold change calculation. C) Immunoblots demonstrating the expression of p63 and p73 isoforms
in p53fl/fl and p53R172H HCC cell lines. Note the presence of multiple isoforms within the cell lines. GAPDH is
used as a loading control. MW =molecular weight marker.
doi:10.1371/journal.pone.0123816.g005
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therefore assessed the levels of p63 and p73 in p53fl/fl- and p53R172H-derived cell lines by im-
munoblotting. We found that p53fl/fl cell lines expressed lower levels of the TA isoforms of p63
and p73 relative to p53R172H cell lines (Fig 5C). We also observed relatively higher expression
of ΔNp63 in p53fl/fl cell lines (Fig 5C). Together, these data suggest that p63 and p73 are inhib-
ited in p53 null HCC cells.
Discussion
Point mutations in the gene encoding the p53 tumor suppressor protein are commonly found
in hepatocellular carcinoma [6–9]. In addition, p53 gene mutation and loss of function is asso-
ciated with tumor progression, poor differentiation status and poor prognosis in this malignan-
cy [8,9]. Moreover, prior work has demonstrated that p53 mutants display gain-of-function
properties in certain contexts [16–19]. Therefore, given the common occurrence of p53 muta-
tions in HCC, we sought to determine whether a frequent tumor-associated mutation, R175H
(R172H in mice) displays gain-of-function properties in HCC.
Consistent with gain-of-function properties, and in line with prior published studies, we
found that mouse HCC cell lines isolated from tumors expressing the p53R172H mutant de-
pended on this mutant for their transformed properties. However, direct comparison of the
phenotypes of HCC cell lines null for p53 and those expressing only mutant p53 demonstrated
that the two classes of cell lines are phenotypically indistinguishable. Thus, while p53R172H is
required for the full transformation properties of HCC cells expressing this mutant protein,
these properties are not greater than those observed in the p53-deficient setting.
These in vitro findings mirror our data from an HCC mouse model in which p53R172H pro-
motes HCC progression and metastasis, but only to a similar extent as p53 nullizygosity. These
findings are in contrast to prior results suggesting that p53 mutants promote the increased de-
velopment of carcinomas relative to p53 loss [20,21], as well as other data demonstrating the
promotion of PDAC metastasis by mutant p53 [16]. However, they are in line with prior work
demonstrating that p53 mutants display dominant-negative, but not gain-of-function proper-
ties during skin carcinogenesis [24]. A possible explanation for the differing results is that dif-
ferent p53 mutants display different properties in different tissues. For example, germline
introduction of the p53R270H mutant resulted in the development of carcinomas, including
HCC, in p53 heterozygous mice, whereas the R172H mutant induced the development of oste-
osarcomas [20]. Therefore, it would be interesting to determine whether other p53 mutants
such as R270H and R246S (corresponding to human hotspots R273H and R249S), display
gain-of-function properties during HCC development in vivo.
It also remains to be seen whether the impact of p53 deficiency versus p53 mutation is de-
pendent on the driving oncogenic lesion. Our mouse model is driven by the expression of the
PyMT oncogene, which robustly activates signaling through the PI3K signaling axis. Indeed,
our prior data demonstrate that abrogation of PyMT-induced activation of PI3K impairs HCC
development [11]. Whether p53 nullizygosity and p53 mutation exert similar effects in liver tu-
mors driven by the expression of commonly activated HCC oncogenes such as MYC and β-
catenin remains to be tested.
Collectively, our results suggest that p53 mutation and p53 deletion result in hepatocellular
tumors with similar functional impairments. Prior work has suggested that one potential
mechanism through which p53 mutants exerted their gain-of-function effects is through the
inhibition of the related transcription factors p63 and p73 [20,21,26]. Further, published exper-
iments demonstrated that p53 mutants could inhibit p63 and p73 transcriptional activity in
HCC cells [22]. We therefore examined the impact of shRNA-mediated p53R172H silencing and
found that the levels of p63- and p73-regulated genes were induced following knockdown of
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mutant p53. Yet, the levels of these target genes were similarly suppressed in p53 null HCC
cells, suggesting that p63 and p73 activity were likewise impaired in these cells. In agreement,
we observed lower TAp63 and TAp73 levels, and higher ΔNp63 levels in p53 null HCC cells
relative to p53R172H-expressing HCC cells. Our data therefore suggest that p63 and p73 may be
critical factors that constrain HCC development in vivo, and their functional inhibition is re-
quired for HCC development and progression. However, the mechanism(s) that impairs their
activity in p53 null cells is currently unknown.
Of note, liver-specific inactivation of p63 or p73 has not been evaluated for its impact on
liver carcinogenesis. These studies will be needed to determine whether p63 or p73 is the criti-
cal protein inactivated during liver tumor development. Perhaps an interesting clue comes
from prior experiments performed by Jacks and colleagues. In their studies, combined inactiva-
tion of p53 and p73, but not p53 and p63, resulted in the development of spontaneous liver tu-
mors in vivo, suggesting that p73 may play a more important role in constraining liver
tumorigenesis than p63 [28]. In agreement, prior work has demonstrated that transgenic ex-
pression of the ΔNp73 isoform induces the formation of liver tumors in vivo [41]. However,
studies directly comparing the tumor suppressive effects of the p63 and p73 transcription fac-
tors in the liver will be required before any conclusions can be drawn regarding their functions
in this tissue.
Supporting Information
S1 Fig. p53R172H tumors express mutant p53. A) Representative images of immunostaining
for p53 in liver tumors induced in p53fl/fl and p53R172H mice. Nuclear p53 staining is observed
in p53R172H tumors but not p53fl/fl tumors. Magnification 100x. B) Genomic DNA isolated
from representative mouse liver tumors were examined by PCR for allelic recombination. In
the top gel, the band representing 1 LoxP site demonstrates that recombination occurred at the
Lox-Stop-Lox cassette in the p53LSL-R172H allele. The lower band, labeled “wild-type” repre-
sents the Trp53 allele that does not contain an LSL cassette. The band on the lower gel repre-
sents recombination of the p53flox allele, demonstrating that deletion of exons 2–10 occurred.
(TIF)
S2 Fig. HCCs induced in p53R172H and p53fl/fl livers display similar proliferation rates. A)
Representative images of Ki67 IHC in normal liver tissue and HCC from p53fl/fl and
p53R172H/flmice from the survival cohort. B) Cells with Ki67-positive and negative nuclei
were counted to obtain the percentage of cells within an HCC section that were Ki67 positive.
Five fields in each tumor section were counted to obtain an average. In each cluster of bars, the
first bar is the quantification of Ki67 staining in a non-tumor bearing liver.
(TIF)
S3 Fig. HCCs induced in p53R172H and p53fl/fl livers metastasize to the lungs. Representative
H&E images of lung metastases identified in mice bearing p53 null and p53R172H-expressing
liver tumors.
(TIF)
S1 Table. Primers for quantitative RT-PCR.
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S2 Table. Tumor and metastasis incidence in p53fl/fl and p53R172H mice.
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